AstraZeneca's Multi-Tumor Opportunity Still Exists
May 18, 2016 at 13:43 PM EDT
AstraZeneca plc (ADR) (NYSE: AZN) announced that Lynparza, which has already received approval for ovarian cancer, failed to meet the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.